Biomarkers: Paving Stones on the Road Towards the Personalized Precision Medicine for Oral Squamous Cell Carcinoma

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2018 Sep 23

PMID 30241505

Citations 16

Authors

Liang Zhong

Yutong Liu

Kai Wang

Zhijing He

Zhaojian Gong

Zhili Zhao

Yaocheng Yang

Xiaofei Gao

Fangjie Li

Hanjiang Wu

Sheng Zhang

Lin Chen

Affiliations

Soon will be listed here.

Abstract

Traditional therapeutics have encountered a bottleneck caused by diagnosis delay and subjective and unreliable assessment. Biomarkers can overcome this bottleneck and guide us toward personalized precision medicine for oral squamous cell carcinoma. To achieve this, it is important to efficiently and accurately screen out specific biomarkers from among the huge number of molecules. Progress in omics-based high-throughput technology has laid a solid foundation for biomarker discovery. With credible and systemic biomarker models, more precise and personalized diagnosis and assessment would be achieved and patients would be more likely to be cured and have a higher quality of life. However, this is not straightforward owing to the complexity of molecules involved in tumorigenesis. In this context, there is a need to focus on tumor heterogeneity and homogeneity, which are discussed in detail. In this review, we aim to provide an understanding of biomarker discovery and application for precision medicine of oral squamous cell carcinoma, and have a strong belief that biomarker will pave the road toward future precision medicine.

Citing Articles

Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.

Glaviano A, Lau H, Carter L, Lee E, Lam H, Okina E J Hematol Oncol. 2025; 18(1):6.

PMID: 39806516 PMC: 11733683. DOI: 10.1186/s13045-024-01634-6.

A new perspective on diagnostic strategies concerning the potential of saliva-based miRNA signatures in oral cancer.

Prasad M, Sekar R, Priya M, Varma S, Karobari M Diagn Pathol. 2024; 19(1):147.

PMID: 39548527 PMC: 11568613. DOI: 10.1186/s13000-024-01575-1.

AI illuminates paths in oral cancer: transformative insights, diagnostic precision, and personalized strategies.

Kapoor D, Saini P, Sharma N, Singh A, Prajapati B, Elossaily G EXCLI J. 2024; 23:1091-1116.

PMID: 39391057 PMC: 11464865. DOI: 10.17179/excli2024-7253.

The role of MicroRNAs in the diagnosis and treatment of oral premalignant disorders.

Fathima J, Jayaraman S, Sekar R, Syed N Odontology. 2024; 112(4):1023-1032.

PMID: 38619695 DOI: 10.1007/s10266-024-00934-0.

Salivary Biomarkers for Oral Cancer Detection: Insights from Human DNA and RNA Analysis.

Navale A, Deshpande A Cardiovasc Hematol Agents Med Chem. 2024; 22(3):249-257.

PMID: 38275030 DOI: 10.2174/0118715257269271231201094946.

References

Zhang L, Jiang J, Arellano M, Zhang L, Yan X, Wong D . Quantification of Serum Proteins of Metastatic Oral Cancer Patients Using LC-MS/MS and iTRAQ Labeling. Open Proteomics J. 2010; 1:72-78. PMC: 2871699. DOI: 10.2174/1875039700801010072. View

Wang Z, Gerstein M, Snyder M . RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2008; 10(1):57-63. PMC: 2949280. DOI: 10.1038/nrg2484. View

Wang Y, Springer S, Mulvey C, Silliman N, Schaefer J, Sausen M . Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci Transl Med. 2015; 7(293):293ra104. PMC: 4587492. DOI: 10.1126/scitranslmed.aaa8507. View

Metgud R, Patel S . Serum and salivary levels of albumin as diagnostic tools for oral pre-malignancy and oral malignancy. Biotech Histochem. 2013; 89(1):8-13. DOI: 10.3109/10520295.2013.793394. View

Liu H, Liu X, Dong G, Zhou J, Liu Y, Gao Y . P16 Methylation as an Early Predictor for Cancer Development From Oral Epithelial Dysplasia: A Double-blind Multicentre Prospective Study. EBioMedicine. 2015; 2(5):432-7. PMC: 4485905. DOI: 10.1016/j.ebiom.2015.03.015. View

Schussel J, Zhou X, Zhang Z, Pattani K, Bermudez F, Jean-Charles G . EDNRB and DCC salivary rinse hypermethylation has a similar performance as expert clinical examination in discrimination of oral cancer/dysplasia versus benign lesions. Clin Cancer Res. 2013; 19(12):3268-75. PMC: 3687013. DOI: 10.1158/1078-0432.CCR-12-3496. View

Lajer C, Nielsen F, Friis-Hansen L, Norrild B, Borup R, Garnaes E . Different miRNA signatures of oral and pharyngeal squamous cell carcinomas: a prospective translational study. Br J Cancer. 2011; 104(5):830-40. PMC: 3048216. DOI: 10.1038/bjc.2011.29. View

Lee E, Luo J, Wilson J, Shi H . Analyzing the cancer methylome through targeted bisulfite sequencing. Cancer Lett. 2012; 340(2):171-8. PMC: 3616138. DOI: 10.1016/j.canlet.2012.10.040. View

Gardner L . Nonsense-mediated RNA decay regulation by cellular stress: implications for tumorigenesis. Mol Cancer Res. 2010; 8(3):295-308. PMC: 2841721. DOI: 10.1158/1541-7786.MCR-09-0502. View

10.

Tabatabaeifar S, Larsen M, Larsen S, Kruse T, Thomassen M, Sorensen J . Investigating a case of possible field cancerization in oral squamous cell carcinoma by the use of next-generation sequencing. Oral Oncol. 2017; 68:74-80. DOI: 10.1016/j.oraloncology.2017.03.018. View

11.

Zhang H, Liu O, Deng C, He Y, Feng Y, Ma J . Genome-wide gene expression profiling of tongue squamous cell carcinoma by RNA-seq. Clin Oral Investig. 2017; 22(1):209-216. DOI: 10.1007/s00784-017-2101-7. View

12.

Yamamoto H, Imai K . Microsatellite instability: an update. Arch Toxicol. 2015; 89(6):899-921. DOI: 10.1007/s00204-015-1474-0. View

13.

Gustafsson J, Oehler M, Ruszkiewicz A, McColl S, Hoffmann P . MALDI Imaging Mass Spectrometry (MALDI-IMS)-application of spatial proteomics for ovarian cancer classification and diagnosis. Int J Mol Sci. 2011; 12(1):773-94. PMC: 3039979. DOI: 10.3390/ijms12010773. View

14.

Xu H, Yang Y, Zhao H, Yang X, Luo Y, Ren Y . Serum miR-483-5p: a novel diagnostic and prognostic biomarker for patients with oral squamous cell carcinoma. Tumour Biol. 2015; 37(1):447-53. DOI: 10.1007/s13277-015-3514-z. View

15.

Marusyk A, Almendro V, Polyak K . Intra-tumour heterogeneity: a looking glass for cancer?. Nat Rev Cancer. 2012; 12(5):323-34. DOI: 10.1038/nrc3261. View

16.

Matharoo-Ball B, Miles A, Creaser C, Ball G, Rees R . Serum biomarker profiling in cancer studies: a question of standardisation?. Vet Comp Oncol. 2009; 6(4):224-47. DOI: 10.1111/j.1476-5829.2008.00171.x. View

17.

Bettegowda C, Sausen M, Leary R, Kinde I, Wang Y, Agrawal N . Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014; 6(224):224ra24. PMC: 4017867. DOI: 10.1126/scitranslmed.3007094. View

18.

Pikor L, Thu K, Vucic E, Lam W . The detection and implication of genome instability in cancer. Cancer Metastasis Rev. 2013; 32(3-4):341-52. PMC: 3843371. DOI: 10.1007/s10555-013-9429-5. View

19.

Strome S, Dong H, Tamura H, Voss S, Flies D, Tamada K . B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 2003; 63(19):6501-5. View

20.

Ge L, Liu S, Xie L, Sang L, Ma C, Li H . Differential mRNA expression profiling of oral squamous cell carcinoma by high-throughput RNA sequencing. J Biomed Res. 2015; 29. PMC: 4585435. DOI: 10.7555/JBR.29.20140088. View